Neuroinflammatory diseases such as multiple sclerosis are characterized by infiltration of lymphocytes into the central nervous system followed by demyelination and axonal degeneration. 
| INTRODUCTION
Oligodendrocyte progenitor cells (OPCs) in the adult central nervous system (CNS) proliferate and differentiate to mature oligodendrocytes which protect and help maintain normal neuronal functions by myelinating axons (Franklin & ffrench-Constant, 2008) . The OPCs may thus play a critical role in the pathogenesis and recovery of neuroinflammatory diseases such as multiple sclerosis (MS), progressive multifocal leukoencephalopathy, neuromyelitis optica, acute disseminated encephalomyelitis, and adrenoleukodystrophy, where infiltration of lymphocytes into the CNS leads to demyelination and axonal degeneration (Franklin, 2002; Gensert & Goldman, 1997; Levine & Reynolds, 1999; Zawadzka et al., 2010) . Further, increased numbers of OPCs and remyelination are usually observed in focal areas infiltrated with activated T cells but less commonly in chronic plaques (Prineas, Barnard, Kwon, Sharer, & Cho, 1993; Wolswijk, 2002) . However, the effect of activated T cells on OPCs in adult brain is unknown. Developing appropriate models to study T cell-OPC interactions has been challenging because rodent OPCs and oligodendrocytes behave differently compared to human cells in their gene expression, response to growth factors, mitotic competence, differentiation, and remyelination potentials (Chandran et al., 2004) . There are also logistical and technical challenges in obtaining and culturing adult human OPCs (Wang et al., 2014) . Recent developments in cellular reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) and subsequent differentiation provide novel opportunities to generate cell types of interest. However, generation of iPSCs and the subsequent differentiation are usually labor intensive and time consuming. Therefore, direct conversion of somatic cells to other cell types by bypassing iPSCs provides another desirable option. Using this approach, neural stem cells have been directly transformed from adult fibroblasts (Han et al., 2012; Ring et al., 2012; Thier et al., 2012) . Recently, we showed that induced neural stem cells (iNSCs) can be derived directly from human adult hematopoietic stem cells using Sendai virus containing Yamanaka factors and neural stem cell selective medium (Wang et al., 2013 (Wang et al., , 2015 . The iNSCs derived from adult CD34 + cells were self-renewing and could be further differentiated into adequate numbers of neurons and glia including OPCs. This provides a unique model to study the effect and mechanism of activated T cells on human OPC functions.
While activated T cells are known to cause neuronal injury, to our surprise we found that these cells release factors that induce proliferation of OPCs. Once activated, T lymphocytes release a variety of inflammatory factors including vascular endothelial growth factor A (VEGF-A) (Mor, Quintana, & Cohen, 2004) . VEGF-A is best known for its essential role in growth of blood vessels and regulation of proliferation and migration of endothelial cells. But VEGF-A has also been implicated in pathological conditions such as disruption of the blood brain barrier in CNS inflammatory diseases (Argaw et al., 2012; Proescholdt et al., 1999; Suidan et al., 2010) , and there is increased expression of VEGF in acute and chronic MS plaques (Proescholdt, Jacobson, Tresser, Oldfield, & Merrill, 2002) . VEGF-A is upregulated in other autoimmune diseases including diabetic retinopathy, macular degeneration, and systemic sclerosis (Kikuchi et al., 1998; Kvanta, Algvere, Berglin, & Seregard, 1996; Pe'er et al., 1996) . There is emerging evidence that VEGF-A also plays a role in a wide range of neuronal functions and in neurogenesis (Mackenzie & Ruhrberg, 2012) . In this study, we used human OPCs differentiated from iNSCs to study the effect of inflammatory factors released from activated T cells on OPC function. We observed that activated T cells released VEGF-A which led to increased proliferation of OPCs through activation of the VEGF receptor 2 (VEGFR2).
| MATERIALS AND METHODS

| Materials
Culture media and components were purchased from Invitrogen (Carlsbad, CA) and growth factors and cytokines were purchased from PeproTech (Rocky Hill, NJ) if not specified.
Blood was collected from deidentified adult healthy donors at the Transfusion Medicine Blood Bank of the National Institutes of Health.
Signed informed consent was obtained in accordance with the NIH Institutional Review Board.
| Generation of iNSCs from adult CD34 + cells
iNSCs were directly generated from CD34 + cells as previously published (Wang et al., 2013 (Wang et al., , 2015 . Briefly, CD34 + cells were purified from cells obtained via leukophoresis using a CD34 MultiSort Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) and cultured in StemSpan SFEM medium (Stemcell technologies, Vancouver, Canada) containing human thrombopoietin (TPO, 100 ng/ml), fmslike tyrosine kinase 3 (Flt-3) ligand (100 ng/ml) and stem cell factor (SCF, 100 ng/ml), interleukin-6 (IL-6, 20 ng/ml), and interleukin-7
(IL-7, 20 ng/ml) in a 6-well plate (3 × 10 5 cells/well in 2 ml of medium per well) at 37 C in 5% CO 2 incubator for 5 days. Cells were replated daily to exclude adherent nonhematopoietic popula- 
| Differentiation of iNSCs into OPCs
OPCs and myelin basic protein (MBP) positive oligodendrocytes were differentiated from iNSCs using a two-step process as previously published (Wang et al., 2013 (Wang et al., , 2015 . For OPC differentiation, 2.5 × 10 4 iNSCs were plated on poly-L-ornithine (Sigma) coated 6-well plates in incubator. The cells were activated by adding CD3/CD28 Dynabeads (Invitrogen) with a bead-to-cell ratio of 1:10 and incubated for 48 hr.
Culture sups were collected and used to treat OPCs or oligodendrocytes with a supernatant-to-medium (OPC induction medium or oligodendrocyte medium) ratio of 1:20.
2.6 | Transfection of HEK293 cells 
| Immunocytochemistry
Immunostaining was performed as previously described (Wang et al., 2013) . Briefly, cells were fixed in 4% (w/v) paraformaldehyde ( 
| Cell proliferation assays
Cell numbers were determined using CellQuanti-Blue Cell Viability
Assay kit (BioAssay Systems, Hayward, CA) per manufacturer's instructions. OPCs were plated in 96-well plates in OPC medium and treated with T cell or HEK293 cell sups (1:20 dilution) for 24 hr at 37 C. CellQuanti-blue reagent (10 μl/well) was added to each well.
After incubation for another hour at 37 C, the fluorescence was quantified at an excitation wavelength of 530 nm and emission wavelength of 590 nm using a fluorescence plate reader. Cell proliferation was measured by EdU incorporation assay. After treatment with T cell sups for 20 hr, OPCs were treated with 10 μM of EdU (Invitrogen) for another 4 hr. The cells were then fixed with 4% paraformaldehyde and EdU labeling was detected using Click-iT EdU Imaging Kits (Invitrogen) per the manufacturer's instructions. DAPI was used for nuclear staining. Images from seven predetermined fields per well were taken and cell proliferation was determined by calculating the ratio of EdU-positive cells to total DAPI-positive cells. 
| Cell cycle evaluation
| Cell viability assay
The cell viability was measured by propidium iodide staining. OPCs were plated in 96-well plates in OPC medium and treated with T cell or HEK293 cell sups (1:20 dilution) for 24 hr at 37 C. Culture plate was centrifuged for 5 min at 400g at room temperature. To each well was added 100 μl of assay binding buffer and plate was centrifuged for 5 min at 400g. Assay binding buffer was discarded and 50 μl of propidium iodide staining solution was added to each well. The plate was centrifuged for 5 min at 400g, and propidium iodide staining solution was discarded. To each well was added 100 μl of assay binding buffer and the fluorescence was quantified at an excitation wavelength of 560 nm and emission wavelength of 595 nm using a fluorescence plate reader.
| VEGF-A immunodepletion and VEGF receptor inhibition
To immunodeplete VEGF-A from T cell sups, the sups were incubated with protein G Dynabeads (Invitrogen) conjugated to VEGF-A antibody (Acris, San Diego, CA) or an isotype-matched control antibody for 18 hr at 4 C. The Dynabead complex was removed using a magnet. The remaining supernatant after bead removal was used as to treat the OPC cultures. To assess the role of VEGF receptor 1 and 2 on proliferation of OPCs the cells were pretreated with VEGFR1 antagonist, ZM306416 (2-10 μM) (Selleckchem, Houston, TX) or VEGFR2 antagonist SU1498 (2-10 μM) (Calbiochem, Billerica, MA) for 30 min followed by incubation with T cell sups for 24 hr. Cell proliferation was assessed by Premo FUCCI Cell Cycle Sensor as described above.
2.14 | Statistical analysis 
| Activated T cells upregulated G1 to S phase transition in OPCs
We used FUCCI to study the effects of activated T cells on cell cycle progression of proliferating OPCs. OPCs were transfected with FUCCI constructs, followed by treatment of sups from activated pan-T cells, phase and S/G 2 /M phases compared to control while there were much more RFP + cells than the GFP + cells (Figure 3a,b) . The number of cells expressing both RFP and GFP were increased as well (Figure 3c ). These results indicate that activated T cell sups increased proliferation of OPCs by increasing the cell numbers in G1 phase and then transitioning them to S phase and eventually leading to cell division which was evidenced by an increase in the number of cells expressing GFP (Figure 3a ).
| VEGF-A released from activated T cells mediated proliferation of OPCs
Previously published gene arrays from activated T cells indicated that VEGF-A was a growth factor produced by these cells (Diehn et al., 2002) . Hence, we used real-time polymerase chain reaction (PCR) to 
| VEGF-A induced OPC proliferation is VEGFR2 dependent
VEGF-A exerts its effects by activating receptor tyrosine kinases, VEGFR1 and VEGFR2. Hence, to determine which receptor on OPCs is responsible for VEGF-A-mediated OPC proliferation, VEGFR1 and VEGFR2 expression on OPCs were determined by western blot analysis. It showed that OPCs expressed VEGFR2 but not VEGFR1 (Figure 5a ). Further, pretreatment of OPCs with VEGFR1 specific inhibitor, ZM306416 (2-10 μM) had no effect on activated pan T cell supernatant-mediated OPC proliferation (Figure 5b ) while pretreatment with VEGFR2-specific inhibitor, SU1498 (2-10 μM) inhibited the proliferation in a dose-responsive manner (Figure 5cii ). No significant toxicity was observed when OPCs were treated with SU1498 at 2-10 μM for 24 hr and assessed by propidium iodide staining (Figure 5ci ). These results suggested that VEGF-A released from activated T cells increased proliferation of OPCs through VEGR2 activation.
| VEGF-A induced proliferation of OPCs derived from human fetal brain
To determine whether VEGF-A released from activated T cells has the same effect on primary OPCs, We first differentiated OPCs and oligodendrocytes from human fetal brain tissues. To confirm the identity of Figure 3) , indicating the trophic effect of activated T cells is specific to OPC proliferation with no effect on oligodendrocyte maturation.
| DISCUSSION
In this study, we determined the effect of activated T cells on OPC proliferation using OPCs differentiated from human iNSCs and further confirmed the results using human fetal brain derived OPCs. We demonstrated that VEGF-A released from activated T cells induce proliferation of OPCs by activating VEGFR2 which promotes G1 to S phase transition of OPCs.
In this study, we used OPCs derived from iNSC which has several advantages. iNSCs can be derived from CD34 cells obtained from blood. The iNSCs can then be expanded to sufficient numbers for in vitro studies (Wang et al., 2015) . Furthermore, we showed that
OPCs differentiated from iNSCs behave in a similar way as OPCs dif- Nevertheless, in patients with neuroinflammatory disorders, using our in vitro model system, lymphocytes from the same patient could be used in an autologous manner to determine its effects on the OPCs derived from the same patient's iNSCs. This would allow for the study of the effects of cell-to-cell contact between the two cell types that cannot be done in an allogeneic system due to MHC mismatch.
T cell activation and infiltration in the brain has been observed in MS and other demyelinating diseases such as acute disseminated encephalomyelitis (Garg, 2003) , neuromyelitis optica (Pohl et al., 2013) , and adrenoleukodystrophy (Ito et al., 2001) . In these disorders, T cell activation has been implicated in causing neurotoxicity and injury to myelin (Garg, 2003; Kutzelnigg & Lassmann, 2014) and most therapeutic strategies prevent T cell infiltration into the brain. However, others have shown that infiltration of activated T cells alone is not sufficient to cause demyelination. In fact in some patients, a fulminant T cell encephalitis may occur in the setting of immune reconstitution syndrome with no evidence of demyelination (Johnson et al., 2013; Venkataramana et al., 2006) . It has been observed that OPCs can be frequently found in MS plaques in the brain but their relationship to T cells had not been studied (Chang, Tourtellotte, Rudick, & Trapp, 2002; Chari & Blakemore, 2002; Wolswijk, 1998) . Following treatment with glatiramer acetate, Th2 cells release insulin growth factor-2 which is also trophic to OPCs (Zhang et al., 2010) . Activated T cells have also been shown to increase proliferation of smooth muscle cells in the respiratory passages in patients with asthma. In this (b) VEGFR1 antagonist, ZM306416, (i) had no effect on OPC viability when incubated alone and (ii) did not inhibit the effect of activated (Act) T cell sups induced GFP+ cell numbers on OPCs. (c) VEGFR2 antagonist, SU1498, (i) had no effect on OPC viability when incubated alone but (ii) inhibited OPC proliferation as indicated by GFP+ cell numbers in a dose-responsive manner in the presence of Act T cell sups. Data represent mean + SEM from three independent experiments. N = 3 for b and c; **p < .005; ***p < .0005 case, the ligand for epidermal growth factor receptor is released by enzymatic cleavage by T cells (Al Heialy et al., 2013) . Thus, activated T cells have a wide range of trophic effects on various cell types which may in part be driven by the factors released and types of receptors expressed on these cells. We now show that activated T cells promote OPC proliferation. We found that there is a significant increase in transcript of bFGF but not PDGF-A (Supporting Information, Figure 4a ,b). While it is known that bFGF and PDGF-AA induce rodent OPC proliferation (Furusho, Roulois, Franklin, & Bansal, 2015) , as bFGF and PDGF-AA were already included in the culture medium, adding more bFGF or PDGF-AA in the culture medium failed to further increase OPC proliferation (Supporting Information, Figure 4c ).
Our result is also in agreement with a report that bFGF and PDGF-AA support human OPC survival but not proliferation (Chandran et al., 2004) . Instead, we found that activated T cells increased expression of VEGF-A which is consistent with other reports (Lyu & Park, 2011; Mor et al., 2004) . We found that OPCs express VEGFR2, activation of which triggers a proliferative response in these cells. These observations indicate that the effect of T cells activation on neural cells could be very complicated. While some factors released from activated T cells such as granzyme B may cause neurotoxicity (Wang et al., 2006) , other factors such as VEGF-A may enhance OPC proliferation and thus has the potential to protect neurons. This also implies that when targeting T cell related inflammation as a therapy for neuroinflammatory disorders, it may be better to target specific inflammatory factors or pathways rather than generally inhibiting T cell activation.
Using iNSC differentiated OPCs as a model, we found that both activated CD4 and CD8 T cells induced OPC proliferation. Among the soluble factors, VEGF-A was upregulated in both CD4 and CD8 cells following activation and was primarily responsible for induction of OPC proliferation through activation of VEGFR2. VEGF-A is well known as a potent and integral regulator of angiogenesis, which contributes to pathogenesis of many diseases, including cancer, rheumatoid arthritis, age-related macular degeneration, and diabetic retinopathy. VEGF is widely expressed in normal and disease conditions, and upregulation occurs at sites of angiogenesis and inflammation. Several lines of evidence have suggested that VEGF is also implicated in neuroinflammatory diseases such as MS. In both chronic and acute MS plaques, VEGF-positive reactive astroglia were widespread and disseminated (Proescholdt et al., 2002) . However, VEGF-A may act as a double-edged sword. In a mouse model of experimental allergic encephalomyelitis, VEGF-A exacerbated the inflammatory response by inducing focal blood-brain barrier (BBB) breakdown, lymphocyte infiltration, and migration of lymphocytes into the lesions (Argaw et al., 2012; Proescholdt et al., 1999; Suidan et al., 2010) . On the other hand, VEGF-A has been shown to promote neurite growth in a nerve injury model (Li, Burns, Han, Rumbaut, & Smith, 2011) and be neuroprotective in motor neuron disease models (Blackburn, Sargsyan, Monk, & Shaw, 2009 not proliferation of OPC (Hayakawa et al., 2011) . The observed differences maybe specie specific since prior studies were done with a murine model while our study was performed with human cells. It is also noteworthy that an increase in OPC numbers may not always be beneficial, as OPCs may also release proinflammatory factors such as MMP9 to disrupt the BBB (Seo et al., 2013) . We evaluated MMP9 gene expression in primary OPCs after treatment with activated T cell sups and did not find a significant change (Supporting Information, Figure 5 ). Although the pathological significance of a single factor such as MMP9 may be limited due to abundance and disease conditions (Savarin et al., 2011) , it still highlights the complexity in targeting inflammation as an intervention to control disease progression.
In summary, we report that OPCs generated from CD34-derived iNSCs behave similarly as primary OPCs in response to soluble factors released from activated T cells and could be used to study the physiological functions and pathogenesis of OPCs, providing a specific advantage especially by using patient-specific blood samples. Further, using this model, we found VEGF-A released from activated T cells could enhance OPC proliferation through activation of VEGFR2, indicating a critical role for VEGF-A in T cell-mediated neuroinflammation.
These findings add to the complexity of the neuropathogenesis of diseases with leukoencephalitis and may have important implications for therapeutic strategies that target activated T cells for treatment of these disorders.
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